According to a Jefferies & Co. research note, Verona Pharma Plc. is at the final stretch for its FDA approval.
According to a Jefferies & Co. research note, Verona Pharma Plc. has a 90-95% probability of success for PDUFA approval.
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note.